Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharma Mar SA ( (ES:PHM) ) has shared an announcement.
Pharma Mar S.A. has convened its Ordinary General Shareholders’ Meeting for June 30, 2026, in Colmenar Viejo, Madrid, with a first call scheduled for June 29 but a second call anticipated due to quorum expectations. Shareholders will have access to all meeting documentation at the company’s offices and website, ensuring transparency ahead of key votes.
The agenda includes approval of the 2025 annual and management accounts, the group’s non‑financial and sustainability reporting, allocation of 2025 results, and a dividend distribution from freely distributable reserves. Investors will also decide on the size and composition of the board, with proposals to appoint two new independent directors, re‑elect four current directors including executive and proprietary members, and address the expiry of mandates for two current directors, signaling a refresh and consolidation of the company’s governance structure.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR121.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
More about Pharma Mar SA
Pharma Mar S.A., based in Spain, operates in the biopharmaceutical sector with a focus likely on oncology and marine-derived therapies, as suggested by its name and market context. The company is listed on Spanish markets and maintains a shareholder base active in attending and voting at general meetings, reflecting a governance framework aligned with local securities regulations.
Average Trading Volume: 71,366
Technical Sentiment Signal: Buy
Current Market Cap: €1.76B
See more data about PHM stock on TipRanks’ Stock Analysis page.